Beneficial pleiotropic vascular effects of rosuvastatin in two hypertensive models
Dinko Susic, MD, PhD*,*,
Jasmina Varagic, MD, PhD*,
Jwari Ahn, MD*,
Michael Slama, MD* and
Edward D. Frohlich, MD*
* Hypertension Research Laboratory, Ochsner Clinic Foundation, New Orleans, Louisiana, USA
View larger version (33K):
[in a new window]
|
Figure 1 Left ventricular coronary hemodynamics in control spontaneously hypertensive rats and rats treated with 1, 5, 10, or 20 mg/kg/day of rosuvastatin for 12 weeks. Twelve to 14 rats per group. Values are means ± 1 SEM. *p < 0.05 when compared with the value under basal conditions; +p < 0.05 when compared with control group.
|
|
View larger version (36K):
[in a new window]
|
Figure 2 Right ventricular coronary hemodynamics in control spontaneously hypertensive rats and rats treated with 1, 5, 10, or 20 mg/kg/day of rosuvastatin for 12 weeks. Twelve to 14 rats per group. Values are means ± 1 SEM. *p < 0.05 when compared with the value under basal conditions; +p < 0.05 when compared with control group.
|
|
|
